WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317191
CAS#: 68475-42-3 (free base)
Description: Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals) is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. Anagrelide works by inhibiting the maturation of platelets from megakaryocytes. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor. The physiologic effect of anagrelide is by means of Decreased Platelet Production. Anagrelide is a synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis.
Hodoodo Cat#: H317191
Name: Anagrelide
CAS#: 68475-42-3 (free base)
Chemical Formula: C10H7Cl2N3O
Exact Mass: 255.00
Molecular Weight: 256.090
Elemental Analysis: C, 46.90; H, 2.76; Cl, 27.69; N, 16.41; O, 6.25
Related CAS #: 68475-42-3 (free base); 58579-51-4 (hydrochloride)
Synonym: Agrelin; Agrylin; Anagrelide; Anagrelide; BL 4162A; Xagrid; Shire; Thromboreductin
IUPAC/Chemical Name: 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
InChi Key: OTBXOEAOVRKTNQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
SMILES Code: C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 256.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Schalling M, Krauth MT, Thiele J, Ruckser R, Gastl G, Gisslinger H. Impact of white blood cells on thrombotic risk in patients with optimised platelet count in essential thrombocythemia. Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13070. [Epub ahead of print] PubMed PMID: 29603799.
2: Rodriguez-Ziccardi M, Rubio M, Lu M, Greenspan A. Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia. BMJ Case Rep. 2018 Feb 8;2018. pii: bcr-2017-220723. doi: 10.1136/bcr-2017-220723. PubMed PMID: 29437800.
3: Bohîlţea RE, Cîrstoiu MM, Ionescu CA, Niculescu-Mizil E, Vlădăreanu AM, Voican I, Dimitriu M, Turcan N. Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review. Medicine (Baltimore). 2017 Nov;96(46):e8735. doi: 10.1097/MD.0000000000008735. Review. PubMed PMID: 29145319; PubMed Central PMCID: PMC5704864.
4: Birgegård G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, Wu J, Achenbach H, Kiladjian JJ. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. 2018 Jan;103(1):51-60. doi: 10.3324/haematol.2017.174672. Epub 2017 Oct 27. PubMed PMID: 29079600; PubMed Central PMCID: PMC5777190.
5: Speirs C, Williams JJL, Riches K, Salt IP, Palmer TM. Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators? Pharmacol Res. 2018 Feb;128:88-100. doi: 10.1016/j.phrs.2017.10.001. Epub 2017 Oct 13. Review. PubMed PMID: 29037480.
6: Cornet N, Vialard F, Mir O, Berveiller P. Is anagrelide safe during pregnancy? J Gynecol Obstet Hum Reprod. 2017 Nov;46(9):697-699. doi: 10.1016/j.jogoh.2017.08.005. Epub 2017 Sep 1. PubMed PMID: 28866127.
7: Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24. PubMed PMID: 28744014; PubMed Central PMCID: PMC5808067.
8: Kanai A, Morokawa H, Matsuda K, Shimazaki E, Nakazawa Y. Efficacy and safety of anagrelide in childhood essential thrombocythemia. Pediatr Int. 2017 Sep;59(9):1017-1018. doi: 10.1111/ped.13330. Epub 2017 Jul 14. PubMed PMID: 28707720.
9: Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Med. 2017 Jun;6(6):1233-1239. doi: 10.1002/cam4.1081. Epub 2017 May 23. PubMed PMID: 28544749; PubMed Central PMCID: PMC5463060.
10: Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res. 2017 Jul;58:14-22. doi: 10.1016/j.leukres.2017.03.008. Epub 2017 Mar 22. Review. PubMed PMID: 28380402; PubMed Central PMCID: PMC5466892.
11: Singh P. A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia. J Pharm Pract. 2018 Apr;31(2):230-233. doi: 10.1177/0897190017699774. Epub 2017 Mar 27. PubMed PMID: 28343445.
12: Na J, Choi SY, Baek S, Lee H. Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia. J Craniofac Surg. 2017 May;28(3):750-751. doi: 10.1097/SCS.0000000000003431. PubMed PMID: 28328595.
13: Kajiguchi T, Kamoshita S, Ito T, Yagi M, Kimura T. Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide. Rinsho Ketsueki. 2017;58(2):119-125. doi: 10.11406/rinketsu.58.119. Japanese. PubMed PMID: 28321088.
14: Petrides PE, Schoergenhofer C, Widmann R, Jilma B, Klade CS. Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product. Clin Pharmacol Drug Dev. 2018 Feb;7(2):123-131. doi: 10.1002/cpdd.340. Epub 2017 Mar 16. PubMed PMID: 28301098; PubMed Central PMCID: PMC5811889.
15: Piccin A, Steurer M, Feistritzer C, Murphy C, Eakins E, Van Schilfgaarde M, Corvetta D, Di Pierro AM, Pusceddu I, Marcheselli L, Gambato R, Langes M, Veneri D, Perbellini O, Pacquola E, Gottardi M, Gherlinzoni F, Mega A, Tauber M, Mazzoleni G, Piva E, Plebani M, Krampera M, Gastl G. Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Transl Res. 2017 Jun;184:21-34. doi: 10.1016/j.trsl.2017.02.001. Epub 2017 Feb 14. PubMed PMID: 28259616.
16: Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Udvardy M, Karádi É, Kellner Á, Egyed M. [An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients]. Orv Hetil. 2017 Jan;158(3):111-116. doi: 10.1556/650.2017.30638. Hungarian. PubMed PMID: 28110571.
17: Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2. PubMed PMID: 27916398.
18: Uz B. Anagrelide may induce acute pancreatitis: the evidences are growing. Ann Hematol. 2017 Jan;96(1):167-168. doi: 10.1007/s00277-016-2850-4. Epub 2016 Oct 18. PubMed PMID: 27752824.
19: Lawless S, McMullin MF, Cuthbert R, Houston R. (32)P in the treatment of myeloproliferative disorders. Ulster Med J. 2016 May;85(2):83-5. PubMed PMID: 27601760; PubMed Central PMCID: PMC4920483.
20: Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. Eur J Haematol. 2017 Feb;98(2):106-111. doi: 10.1111/ejh.12806. Epub 2016 Sep 19. PubMed PMID: 27557754.
